Associate Professor Chris Barnes is a clinical and laboratory haematologist.
He is Director of the Henry Ekert Haemophilia Treatment Centre at the Royal Children’s Hospital and has a particular interest in the diagnosis and management of non – malignant haematological conditions including thrombosis and bleeding disorders.
Haemophilia and bleeding disorders
Quality of life of patients with haemophilia
Pharmakoinetics of clotting factor concentrates
Diagnosis of Diamond Blackfan anaemia
Immune thrombocytopenia pupura and the use of thrombopoietin agonists.
Furmedge J, Lima S, Monagle P, Barnes C, Newall F ‘I don’t want to hurt him.’ Parents’ experiences of learning to administer clotting factor to their child. Haemophilia. 2012 Oct 8.
Howman R, Barnes C, Curtin J, Price J, Robertson J, Russell S, Seldon M, Suppiah R, Teague L, Barrese G. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review. Haemophilia. 2011 May;17(3):463-9.
Teoh Y. Greenway A. Savoia H. Monagle P. Roy J. Barnes C. Hospitalisations for sickle-cell disease in an Australian paediatric population. Journal of Paediatrics & Child Health. 49(1):68-71, 2013 Jan.
Howman R. Barnes C. Curtin J. Price J. Robertson J. Russell S. Seldon M. Suppiah R. Teague L. Barrese G. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE, in children with von Willebrand disorder: a multi-centre retrospective review. Haemophilia. 17(3):463-9, 2011 May
Brown SA. Barnes C. Curtin J. Dunkley S. Ockelford P. Phillips J. Rowell J. Smith M. Tran H. Hematology working group. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.[Erratum appears in Intern Med J. 2013 Jan;43(1):106] Internal Medicine Journal. 42(11):1243-50, 2012 Nov.
Furmedge J. Lima S. Monagle P. Barnes C. Newall F. ‘I don’t want to hurt him.’ Parents’ experiences of learning to administer clotting factor to their child. Haemophilia. 19(2):206-11, 2013 Mar.
Yeoh ZH. Furmedge J. Ekert J. Crameri J. Curtis N. Barnes C. Central venous access device-related infections in patients with haemophilia Journal of Paediatrics & Child Health. 49(3):242-5, 2013 Mar.
Alexander M. Barnes C. Barnett P. Prospective audit of patients with haemophilia: bleeding episodes and management. Journal of Paediatrics & Child Health. 48(2):177-9, 2012 Feb.
Barnes C. Importance of pharmacokinetics in the management of hemophilia. [Review] Pediatric Blood & Cancer. 60 Suppl 1:S27-9, 2013.
Broderick CR. Herbert RD. Latimer J. Barnes C. Curtin JA. Mathieu E. Monagle P. Brown SA Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 308(14):1452-9, 2012 Oct 10.
Barnes, C Brown, SA Curtin, J and Dunkely S When is enough … enough? Developing consensus of definition of failure of immune tolerance induction in patients with haemophilia and inhibitors. Haemophilia2014 Jul;20(4):e275-9. doi: 10.1111/hae.12442.
Orme, LM Babl, FE Barnes, C Barnett, C Barnett, P Donath, S and Ashely, D Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: A randomised trial. Pediatr Blood Cancer 2014 Aug;61(8):1427-33. doi: 10.1002/pbc.25012. Epub 2014 Mar 6.
Rizzi M and Barnes, C A diagnostic approach to a child with a thrombosis in Sickkids Handbook of Paediatric Thormbosis and Haemostasis Editors Blanchette, V Breakley V and Revel – Vilk, S Karger
Saxon, B and Barnes, C Abnormal bleeding and clotting Practical Paediatrics, 7th Edition Churchill Livingstone 2012